Calico abbvie



ABBV-CLS-7262 for ALS

HEALEY ALS Platform Trial Regimen F

Calico Life Sciences in collaboration with AbbVie

Calico

Founded by Art Levinson and Google (now Alphabet) in 2013

Mission: To understand human aging and develop therapies for age-related disorders, including neurodegeneration

obbvie

Partnership with AbbVie, a global biopharmaceutical company with a proven track record of developing medicines and solutions for people living with neuropsychiatric disorders such as Parkinson's Disease, schizophrenia, and depression




What is the Integrated Stress Response (ISR)?





The Integrated Stress Response (ISR)



Lack of essential proteins Toxic levels of stress proteins Build-up of TDP-43 aggregates **Cell death**





Normal protein synthesis

No ISR

elF2

elF2B

Normal proteins



Reduced protein synthesis Production of stress proteins

Formation of TDP-43 stress granules

Transient ISR

Stress 🖌

elF2



Stress granule

What happens to the ISR in individuals with ALS?




abbvie

The ISR in ALS

The ISR is activated in people with ALS causing:


- Reduction in normal protein synthesis
- Increase in production
 of stress proteins
- Formation of stress granules containing TDP-43


abbvie





TDP-43 aggregates are a hallmark of ALS pathology






Ling et al., Neuron 2013

How does the ISR inhibitor work?





The first ISR inhibitor, ISRIB

ISRIB bound to Human eIF2B



Discovered at UCSF by **Carmela Sidrauski** Principal Investigator Calico Life Sciences LLC





ISRIB binds to eIF2B in the central pocket

- Increases the enzymatic activity of eIF2B
- Makes eIF2B less sensitive to stress




ISRIB makes cells less sensitive to stress



ISRIB attenuates induction

of stress protein ATF4

ATF4






What elF2B testing has been done so far?






elF2B activators dissolve TDP-43 stress granules in human motor neurons


Activating the ISR drives TDP-43 into stress granules



TDP-43 Staining of Stressed Human Motor Neurons in Cell Culture




Without treatment




With treatment



elF2B activators rescue mice from neurological deficits caused by a persistent ISR in the brain and spinal cord



elF2B activators protect neurons from dying after injury



How can elF2B activators potentially treat ALS?



elF2B activators may help motor neurons survive harmful stress conditions by:




Restoring normal protein production in stressed nerve cells



Reducing stress proteins that may lead to nerve cell death



Dissolving stress granules that may lead to TDP-43 aggregates



Lack of essential proteins Toxic levels of stress proteins Build-up of TDP-43 aggregates

> Cell death Neurodegeneration ALS

↑ Protein synthesis
 ↓ Stress proteins
 ↓ Further TDP-43 sequestration

Improve cell function

LEGEND



abbvie









Has ABBV-CLS-7262 been given to people?





Results from the first study in healthy people



ABBV-CLS-7262, our clinical eIF2B activator, has been given to over

100 HEALTHY VOLUNTEERS **ABBV-CLS-7262** has favorable drug properties; it can be administered by mouth once a day

ABBV-CLS-7262 was safe across a wide range of doses.

Adverse events were *non-serious* and generally similar between people treated with ABBV-CLS-7262 and placebo


ABBV-CLS-7262 increased eIF2B activity and inhibited the ISR as expected by its mechanism of action

The drug entered the cerebrospinal fluid and was present at concentrations that can fully activate eIF2B





ABBV-CLS-7262 increased eIF2B activity and inhibited the ISR in blood cells collected from trial participants



Placebo

ABBV-CLS-7262



abbvie

19

Has ABBV-CLS-7262 been given to people with ALS?






Preliminary safety information from an ongoing study in people with ALS

The most frequent adverse events possibly related to ABBV-CLS-7262 were*:

Nausea	7%	
Itchiness	7%	
Constipation	7%	
Dizziness	7%	
Headache	10%	



We are excited that ABBV-CLS-7262 will be the next regimen (F) in the Healey ALS Platform Trial



ABBV-CLS-7262 will be taken by mouth once daily

Participants will be randomly assigned to receive active drug or placebo in a 3:1 ratio


Participants will be randomized to 1 of 2 dose levels, both of which are predicted to be pharmacologically active





All participants will receive active drug for at least 1 year

Biomarker collection in Regimen F will expand our understanding of ALS



Cerebrospinal fluid (CSF, fluid surrounding the brain and spinal cord) is collected by lumbar puncture at the beginning of the trial and at the end of the RCT

Blood will be collected periodically

These samples will measure biomarker concentrations to better understand:

- The biology of ALS and role of the ISR
- The effect of ABBV-CLS-7262 on the ISR in the brain and spinal cord
- Which people with ALS may respond better to ABBV-CLS-7262

In summary...



ABBV-CLS-7262 is ready to be evaluated as a new potential treatment for ALS

Problem	Calico
ISR is activated in ALS	ABBV-CLS-7262 is a potent inhibitor of the ISR by binding to, and activating, eIF2B
Aggregates of the protein TDP-43 are observed in most ALS cases	ABBV-CLS-7262 dissolves stress granules containing TDP-43 which may reduce formation of new TDP-43 aggregates
Drugs tested in ALS clinical trials must have their intended biological effect in people	Blood cells from people given ABBV-CLS-7262 show increased eIF2B activity and reduced ISR
The right dose needs to be administered in clinical trials	ABBV-CLS-7262 was measured in the CSF at levels predicted to be pharmacologically active at tolerated doses
Our understanding of ALS is incomplete	CSF and blood samples will improve our understanding of the ISR in ALS and may identify people most likely to respond to ABBV-CLS-7262



Questions

Learn more about Calico and our clinical trials:

calicolabs.com/patients



Watch this video explaining the ISR and its connection to ALS ...